Featured Videos & Audios
Here you will find some of our featured presentations and interviews.
Chief Science Officer Dr. C. David Pauza Presents at Cell & Gene Meeting On The Mesa 2019
The Cell & Gene Meeting on the Mesa is a three-day conference bringing together senior executives and top decision-makers in the industry with the scientific community to advance cutting-edge research into cures. Dr. Pauza was a featured presenter at the conference (press release). In his presentation, he announced details about AGT's pending submission of an IND for a cell & gene therapy for HIV.
EXECUTIVE LEADERSHIP RADIO SHOW ON WFED 1500AM INTERVIEWED CEO JEFF GALVIN
On July 7, 2019, Executive Leadership Radio hosts Herb Cohen and Jeffrey E. Mack interviewed CEO Jeff Galvin. This interview gets to the heart of Galvin's life story, his parents, his experience growing up in Massachusetts, and what led him to the Washington, D.C. area to found American Gene Technologies.
Show is aired on: WFED Federal News Radio 1500 AM
Gene Technologies are Making Strides to Cure Terminal Illnesses
Even if you work in the D.C. region, you may not be privy to a world-changing industrial revolution happening right now, in places around the world. To talk about that is Jeff Galvin, CEO and founder of American Gene Technologies. Galvin is an expert on how innovations in gene research can begin to change the world.
Dr. David Pauza, Chief Science Officer
Explains Why He's Determined To Cure HIV. Watch his story.
C. David Pauza, Ph.D. is Chief Science Officer for American Gene Technologies and Professor of Medicine at the University of Maryland Medical School in Baltimore. Prior to joining AGT, Dr. Pauza was Associate Director for the university’s prestigious Institute of Human Virology and Co-Leader of the Greenebaum Cancer Center Program in Viral Oncology. He is an internationally recognized expert in human virology and viral diseases including HIV, arenaviruses, poxviruses and herpesviruses. He has published more than 150 scientific papers and holds 7 US patents.
BIO2019 PRESENTATION: JEFF GALVIN SPEAKS TO AUDIENCE ABOUT AGT'S SCIENCE, EXPERTS, AND PLANS FOR FDA IND SUBMISSION
On June 4th between 1:45 –2:00 pm, CEO Jeff Galvin spoke to audiences attending BIO2019 about AGT's scientific discoveries, its team of experts, and its plan to move its pre-clinical therapies into the clinic. BIO (Biotechnology Innovation Organization) is the largest trade organization in the world that represents the biotechnology industry.
Built For Bio: Jeff Galvin, CEO & Founder of American Gene Technologies
Montgomery County Economic Development Corporation (MCEDC) discovers how CEO Jeff Galvin is using the availability of raw talent and novel technology unique to Montgomery County, Maryland to help cure HIV and cancers with gene and cell therapy research.
Jeff Galvin Presents at ARM's 7th Annual Cell & Gene Therapy Investor Day
CEO Jeff Galvin presents at Alliance for Regenerative Medicine (ARM)’s 7th Annual Cell & Gene Therapy Investor Day. The event provides institutional, strategic and venture investors with unique insight into financing opportunities for cell and gene therapy-based treatment and tools.
Dr. Ely Benaim, Scientific Advisor
Explains Why He Believes In AGT's Science. Dr. Ely Benaim has spent 25 years in healthcare, has 15 years of clinical experience in academia, government, pharma, and has worked at St. Jude Children's Research Hospital, Amgen, Sangamo Therapeutics, Takeda, and more. Learn why he believes in AGT as a scientific advisor for its HIV cure program. Watch his story.
State Recognizes AGT as a Maryland Success Story
The State of Maryland recognizes American Gene Technologies as a Maryland Success Story because of the accelerated progress it is making to reshape how deadly diseases are treated through gene and cell therapy cures. CEO Jeff Galvin talks with Maryland about the company's success in the State.
IS THE CURE FOR CANCER RIGHT AROUND THE CORNER?...
HOW CREATIVITY CURES | JEFF GALVIN,
AGT CEO | TEDxGEORGETOWN
CEO Jeff Galvin tours nationally to evangelize AGT’s mission and raise awareness of AGT’s commitment to pursuing solutions for patients suffering from intractable diseases. Watch his latest TEDx talk to learn about the tremendous potential and progress in gene and cell therapy, and what AGT and other biotechs are doing to treat (and even cure!) serious human health conditions such as cancers and HIV.
AGT VIRAL VECTOR TECHNOLOGY AND INDUSTRY OVERVIEW
Advances in gene technologies and the resulting cures are accelerating exponentially while costs are coming down. If you were in Silicon Valley for the last 35 years, you’d recognize parallels to many previous high-tech “explosions” such as microcomputers, software and the Internet. “Moore’s Law” now applies to drug development and the next big startup could be up in a garage near you! Forget zeroes and ones… A-C-G-T is the new growth area of programming and real-world solutions. Viva la revolution!
JEFF GALVIN, AGT CEO, INTERVIEWED BY GUY FLYNN (DLA/PIPER PARTNER) FOR CITYBIZLIST ON AGT HISTORY, TECHNOLOGY AND PROGRESS
A national media company, CityBizList, published an interview with Jeff Galvin in a three part “CEO Interview” series. Feedback from viewers indicated that it gives an easy-to-understand background and explanation of AGT’s work and mission. If you are interested, you can view the three part interview below.
Jeff Galvin meets Dr. Roscoe Brady:
AGT is born
How gene and cell therapy will change the world and disrupt the pharmaceutical market
How AGT is using HIV to cure HIV! The future of gene technologies Part 3
AGT’S CSO, C. DAVID PAUZA, PHD, GIVES KEYNOTE SPEECH AT THE CELL AND GENE MEETING ON THE MESA
C. David Pauza, PhD, Chief Science Officer at American Gene Technologies (AGT), presented twice at The Cell and Gene Meeting on the Mesa conference hosted by the Alliance for Regenerative Medicine (ARM). His company presentation focused on the status and progress of AGT’s development of an HIV cure (human trials currently forecast by AGT to begin in 2018). Dr. Pauza also gave the keynote presentation elaborating on how the industry is benefiting from an understanding of and continued research into the human immune system that is opening opportunities to address a wide variety of diseases utilizing gene and cell therapies.
AGT CEO AND FOUNDER, JEFFREY A. GALVIN, GIVES PRESENTATION AT NOBLECON13
Watch CEO Jeff Galvin’s presentation at NobleCon to hear the pitch. His vision for AGT and biotech is infectious. “There is a revolution in drug development that very few people realize…we can attack diseases at their root cause. Gene technology is extremely powerful and it works”.